Literature DB >> 8104031

Replacement of chlorpromazine with other neuroleptics: effect on abnormal skin pigmentation and ocular changes.

S Lal1, D Bloom, B Silver, B Desjardins, B Krishnan, J Thavundayil, T Thompson.   

Abstract

This paper describes the outcome of 15 patients with chlorpromazine (CPZ)-induced abnormal skin pigmentation (ASP) in whom CPZ was replaced with other neuroleptics for three to 13 years. Complete resolution of ASP occurred over a period of six months to five years following substitution with haloperidol (four patients), levomepromazine (three patients), trifluoperazine (one patient), thioproperazine (one patient) as the sole neuroleptic, by a combination of two of the three phenothiazines (four patients) or haloperidol plus pipotiazine (one patient). Resolution was maintained during the remainder of the follow-up period. In one patient, at final follow-up, marked improvement was present three years after CPZ was replaced with levomepromazine. Bilateral lenticular pigmentary deposits persisted in all eight patients examined 3.3 to 13 years after replacing CPZ and less than three months to nine years after resolution of ASP; improvement was noted in only one of these patients. Bilateral endothelial corneal deposits, present in five patients while on CPZ therapy, had disappeared in two patients seven and 13 years, respectively, after replacing CPZ; improvement was noted in two other patients. These findings indicate that: 1. CPZ-induced ASP is completely reversible in most, if not all, patients if CPZ is withdrawn; 2. a variety of neuroleptics including other phenothiazines can be used to replace CPZ without risk of re-emergence of ASP; 3. CPZ-induced lenticular changes persist whereas corneal changes may resolve slowly over a period of many years following replacement of CPZ; 4. ASP and ocular changes induced by CPZ may be subserved by two different pathophysiological mechanisms.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104031      PMCID: PMC1188526     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  33 in total

1.  Deposits in the lens and cornea of the eye during long-term chlorpromazine medication.

Authors:  K Rasmussen; L Kirk; A Faurbye
Journal:  Acta Psychiatr Scand       Date:  1976-01       Impact factor: 6.392

2.  Chlorpromazine and the eye of the dog. VI. A comparison of phenothiazine tranquilizers.

Authors:  C N Barron; T E Murchison; L F Rubin; M L Rubin; W Herron; M Muscarella; H Birkhead
Journal:  Exp Mol Pathol       Date:  1972-04       Impact factor: 3.362

3.  Pigmentation after thioridazine.

Authors:  H Berger
Journal:  Arch Dermatol       Date:  1969-10

4.  Prognosis of eye complications caused by phenothiazines.

Authors:  F M Forrest; H L Snow
Journal:  Dis Nerv Syst       Date:  1968-03

5.  Schizophrenia melanosis. Iatrogenic--congenital defect?

Authors:  A C Grener
Journal:  Dis Nerv Syst       Date:  1968-03

6.  Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study.

Authors:  R F Prien; S L DeLong; J O Cole; J Levine
Journal:  Arch Gen Psychiatry       Date:  1970-11

7.  Rabbit as a model for chlorpromazine-induced hyperpigmentation of the skin.

Authors:  I S Forrest; J C Kosek; R C Aber; M T Serra
Journal:  Biochem Pharmacol       Date:  1970-03       Impact factor: 5.858

Review 8.  Ocular and cutaneous effects of chronic phenothiazine therapy.

Authors:  W S Bond; G C Yee
Journal:  Am J Hosp Pharm       Date:  1980-01

9.  Neuroleptic-induced skin pigmentation in chronic hospitalized schizophrenic patients.

Authors:  T A Ban; W Guy; W H Wilson
Journal:  Can J Psychiatry       Date:  1985-10       Impact factor: 4.356

10.  Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation.

Authors:  D G Ewing; T R Einarson
Journal:  Am J Psychiatry       Date:  1981-12       Impact factor: 18.112

View more
  6 in total

1.  Chlorpromazine-induced cutaneous pigmentation--effect of replacement with clozapine.

Authors:  S Lal; S Lal
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

2.  Chlorpromazine-induced skin pigmentation with short-term use in a patient with bipolar disorder: a case report.

Authors:  Santosh Loganathan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

3.  Rash and desquamation associated with risperidone oral solution.

Authors:  Beang-Jin Chae; Byung-Jo Kang
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

4.  Methotrimeprazine-induced corneal deposits and cataract revealed by urine drug profiling test.

Authors:  Seong Taeck Kim; Jae Woong Koh; Joon Mo Kim; Won Young Kim; Gwang Ju Choi
Journal:  J Korean Med Sci       Date:  2010-10-26       Impact factor: 2.153

5.  A Case Report: Anti-Psychotic Agents Related Ocular Toxicity.

Authors:  Bonnie Nga Kwan Choy; Alex Lap Ki Ng; Jennifer Wei Huen Shum; Michelle Ching Yim Fan; Jimmy Shiu Ming Lai
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 6.  Drug-induced corneal deposits: an up-to-date review.

Authors:  Jean-Yves Sahyoun; Saama Sabeti; Marie-Claude Robert
Journal:  BMJ Open Ophthalmol       Date:  2022-03-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.